Assessment of acute coronary syndromes: focus on novel biomarkers
D Tousoulis1, G Hatzis, N Papageorgiou
11st Cardiology Unit, Athens University Medical School, Greece. drtousoulis@hotmail.com
Insights
New biomarkers show promise for detecting early myocardial ischemia and assessing risk in acute coronary syndromes (ACS). Current methods lack sensitivity and specificity for identifying ischemic heart muscle and predicting future cardiac events.
Area of Science:
- Cardiology
- Biomarker Research
- Atherosclerosis
Background:
- Coronary artery disease (CAD) is a major cause of death globally.
- Inflammation drives plaque formation and rupture in CAD, leading to ischemia and myocardial necrosis.
- Existing biomarkers for myocardial ischemia and necrosis lack optimal sensitivity and specificity.
Purpose of the Study:
- To review emerging biomarkers for early detection of myocardial ischemia.
- To discuss the clinical utility of these novel biomarkers in acute coronary syndromes (ACS).
Main Methods:
- Literature review of recent studies on atherosclerosis biomarkers.
- Analysis of biomarker roles in the pathogenesis and clinical course of CAD.
- Evaluation of biomarker potential for early ischemia detection and risk stratification.
Main Results:
- Several biomarkers implicated in atherosclerosis show potential for early myocardial ischemia detection.
- These novel biomarkers may offer improved sensitivity and specificity compared to traditional markers.
- Evidence suggests their utility in risk assessment for patients with ACS.
Conclusions:
- A need exists for sensitive and specific biomarkers for early myocardial ischemia detection.
- Emerging biomarkers hold promise for improving clinical management of ACS patients.
- Further research is warranted to validate their role in routine clinical practice.
Abstract:
Coronary artery disease (CAD) is the leading cause of mortality in Western Societies and several developing countries. Recent evidence suggests that most detrimental clinical manifestations of CAD, such as acute coronary syndromes (ACS), are the outcome of inflammatory processes that lead to plaque formation and rupture and eventually to ischemia and potentially myocardial necrosis. Neither of the traditionally used biomarkers is thought to be the gold standard in detection of myocardial ischemia or necrosis. A biomarker that could detect quite early the ischemic myocardium as well as define the risk of a future event with high sensitivity and specificity is still lacking. Several biomarkers, implicated in the pathogenesis and clinical evolution of atherosclerosis, have emerged as potent biomarkers for early detection of myocardial ischemia. In the current review, we summarize recent evidence of the most promising biomarkers and discuss their potential role in clinical practice in patients suffering from ACSs.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome I: Introduction
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:26Acute Coronary Syndrome V: Nursing Management
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...